{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rybelsus+Tablet",
    "query": {
      "intervention": "Rybelsus Tablet"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T15:49:18.995Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06374875",
      "title": "Fibrosis Lessens After Metabolic Surgery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)",
        "Non-Alcoholic Fatty Liver Disease",
        "Metabolic Dysfunction-Associated Steatohepatitis (MASH)",
        "Liver Fibrosis",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Metabolic surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Incretin-Based Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-07-11",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-09-08T15:49:18.995Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06374875"
    },
    {
      "nct_id": "NCT06446531",
      "title": "Prevention of Progression of Prediabetes, Obesity and CV Risk",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pre-Diabetes",
        "Weight, Body",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rybelsus Tablet",
          "type": "DRUG"
        },
        {
          "name": "Jardiance 25Mg Tablet",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Actos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2024-09-11",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-09-08T15:49:18.995Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06446531"
    },
    {
      "nct_id": "NCT03919929",
      "title": "Treating PCOS With Semaglutide vs Active Lifestyle Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "PCOS",
        "Adolescent Obesity",
        "NAFLD"
      ],
      "interventions": [
        {
          "name": "Semaglutide 3mg and 7mg [Rybelsus]",
          "type": "DRUG"
        },
        {
          "name": "Weight loss diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "21 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 21 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2019-05-03",
      "completion_date": "2023-10-03",
      "has_results": true,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-09-08T15:49:18.995Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03919929"
    },
    {
      "nct_id": "NCT05035082",
      "title": "A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "semaglutide",
          "type": "DRUG"
        },
        {
          "name": "oral glucose-lowering medications (commercially available)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1018,
      "start_date": "2021-09-01",
      "completion_date": "2025-06-18",
      "has_results": true,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-09-08T15:49:18.995Z",
      "location_count": 25,
      "location_summary": "Alhambra, California • Costa Mesa, California • La Jolla, California + 20 more",
      "locations": [
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05035082"
    },
    {
      "nct_id": "NCT06699329",
      "title": "A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Enlicitide Decanoate",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 38,
      "start_date": "2024-01-22",
      "completion_date": "2024-05-24",
      "has_results": false,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-09-08T15:49:18.995Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06699329"
    },
    {
      "nct_id": "NCT06338553",
      "title": "GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Semaglutide (Rybelsus®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2024-06-12",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-09-08T15:49:18.995Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06338553"
    },
    {
      "nct_id": "NCT06579105",
      "title": "Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo (placebo matching AZD5004 film-coated tablet)",
          "type": "DRUG"
        },
        {
          "name": "AZD5004",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 406,
      "start_date": "2024-10-08",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-09-08T15:49:18.995Z",
      "location_count": 50,
      "location_summary": "Mobile, Alabama • Sheffield, Alabama • Vestavia Hills, Alabama + 47 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Vestavia Hills",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06579105"
    },
    {
      "nct_id": "NCT05892432",
      "title": "Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Semaglutide 3 MG [Rybelsus]",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide 7 MG [Rybelsus]",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-01-11",
      "completion_date": "2025-11-15",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-09-08T15:49:18.995Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05892432"
    }
  ]
}